Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Squamous cell cancer (SCC) is a type of skin cancer. To determine the severity of SCC, doctors use a staging system. There are five stages in total, ranging from 0 to 4. SCC stages describe the ...

A new study published in Engineering has identified enolase 2 (ENO2) as a key factor in the lymphatic metastasis of head and ...

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

The greater the number of risk factors in patients with cutaneous squamous cell carcinoma, the higher the likelihood of poor ...

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck squamous cell carcinoma (HNSCC). The research identified enolase 2 (ENO2), a ...

The FDA has approved Tevimbra with chemotherapy for the first-line treatment of unresectable or metastatic ESCC whose tumors express PD-L1.

Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal ...

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a ...

BeiGene’s Tevimbra (tislelizumab) has been recommended by the European Medicines Agency’s human medicines committee as part of a first-line combination treatment for an aggressive form of lung cancer.